[go: up one dir, main page]

NO20084593L - Okulaere allergibehandlinger - Google Patents

Okulaere allergibehandlinger

Info

Publication number
NO20084593L
NO20084593L NO20084593A NO20084593A NO20084593L NO 20084593 L NO20084593 L NO 20084593L NO 20084593 A NO20084593 A NO 20084593A NO 20084593 A NO20084593 A NO 20084593A NO 20084593 L NO20084593 L NO 20084593L
Authority
NO
Norway
Prior art keywords
ocular allergy
allergy treatments
treatments
ocular
alkaftadine
Prior art date
Application number
NO20084593A
Other languages
English (en)
Other versions
NO341147B1 (no
Inventor
Jagdish Parasrampuria
Avner Ingerman
Frans Janssens
Anton Megens
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084593(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Publication of NO20084593L publication Critical patent/NO20084593L/no
Publication of NO341147B1 publication Critical patent/NO341147B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sammensetninger, kit og fremgangsmåter for behandling eller hindring av okulære allergier og inflammasjon og symptomer derav som innbefatter alkaftadin eller et farmasøytisk akseptabelt salt derav.
NO20084593A 2006-03-31 2008-10-29 Alkaftadin samt oftalmisk sammensetning for anvendelse i behandling av okulær allergi og et kit NO341147B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19
PCT/US2007/064911 WO2007117971A2 (en) 2006-03-31 2007-03-26 Ocular allergy treatments

Publications (2)

Publication Number Publication Date
NO20084593L true NO20084593L (no) 2008-10-29
NO341147B1 NO341147B1 (no) 2017-09-04

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084593A NO341147B1 (no) 2006-03-31 2008-10-29 Alkaftadin samt oftalmisk sammensetning for anvendelse i behandling av okulær allergi og et kit

Country Status (29)

Country Link
US (8) US8664215B2 (no)
EP (2) EP2004196B1 (no)
JP (3) JP5292277B2 (no)
KR (1) KR101321731B1 (no)
CN (1) CN102895234A (no)
AR (1) AR060278A1 (no)
AU (1) AU2007234957B2 (no)
BR (1) BRPI0710085B8 (no)
CA (1) CA2648115C (no)
CL (1) CL2007000916A1 (no)
CR (1) CR10414A (no)
DK (2) DK2004196T3 (no)
EA (1) EA016221B1 (no)
EC (1) ECSP088786A (no)
ES (2) ES2752823T3 (no)
IL (1) IL194473A (no)
JO (1) JO3358B1 (no)
MX (1) MX2008012657A (no)
MY (1) MY153669A (no)
NI (1) NI200800261A (no)
NO (1) NO341147B1 (no)
NZ (1) NZ571690A (no)
PE (1) PE20080053A1 (no)
PL (2) PL3150209T3 (no)
SG (1) SG170044A1 (no)
TW (2) TWI450721B (no)
UY (1) UY30254A1 (no)
WO (1) WO2007117971A2 (no)
ZA (1) ZA200809327B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571690A (en) 2006-03-31 2011-09-30 Vistakon Pharmaceuticals Llc Ocular allergy treatments using alcaftadine
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
MX2010005012A (es) * 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
EP3943069B1 (en) 2009-03-17 2024-11-27 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014080259A1 (en) * 2012-11-21 2014-05-30 Enaltec Labs Pvt. Ltd. Novel polymorphic forms of alcaftadine
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
WO2018031973A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
JPWO2019026992A1 (ja) * 2017-08-03 2020-06-18 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
DK3740191T3 (da) * 2018-01-18 2021-06-07 Faes Farma Sa Oftalmiske sammensætninger omfattende bilastin, et beta-cyclodextrin og mindst et geleringsmiddel
WO2021255622A1 (en) 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
JP2024508811A (ja) 2021-02-24 2024-02-28 オキュラ セラピューティクス，インコーポレイテッド 小管内デポーインサータ装置
CA3213156A1 (en) * 2021-04-01 2022-10-06 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
EP4534081A1 (en) * 2022-07-06 2025-04-09 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
CN116473937A (zh) * 2022-11-29 2023-07-25 嘉兴学院 一种具有抗恶性黑素瘤作用的仿生纳米颗粒及制备方法和应用
WO2024204749A1 (ja) * 2023-03-31 2024-10-03 ロート製薬株式会社 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) * 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
CA2093797C (en) * 1990-10-10 1998-09-22 Richard J. Friary Substituted imidazobenzazepines and imidazopyridoazepines
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077302A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
TWI454286B (zh) * 2006-03-17 2014-10-01 Johnson & Johnson Vision Care 安定氧化性不安定組合物之方法
NZ571690A (en) 2006-03-31 2011-09-30 Vistakon Pharmaceuticals Llc Ocular allergy treatments using alcaftadine

Also Published As

Publication number Publication date
CA2648115A1 (en) 2007-10-18
US20080051385A1 (en) 2008-02-28
AR060278A1 (es) 2008-06-04
UY30254A1 (es) 2007-08-31
BRPI0710085A2 (pt) 2011-08-23
CR10414A (es) 2009-02-23
IL194473A (en) 2016-04-21
PL2004196T3 (pl) 2017-01-31
EP3150209B1 (en) 2019-07-24
JP6039716B2 (ja) 2016-12-07
TWI450721B (zh) 2014-09-01
US20210030762A1 (en) 2021-02-04
CN102895234A (zh) 2013-01-30
PL3150209T3 (pl) 2020-03-31
NZ571690A (en) 2011-09-30
TW201446249A (zh) 2014-12-16
US20140107102A1 (en) 2014-04-17
AU2007234957B2 (en) 2012-12-13
JO3358B1 (ar) 2019-03-13
BRPI0710085B8 (pt) 2021-05-25
KR101321731B1 (ko) 2013-10-30
TWI578990B (zh) 2017-04-21
ES2594655T3 (es) 2016-12-21
MY153669A (en) 2015-03-13
JP2013144703A (ja) 2013-07-25
KR20080110881A (ko) 2008-12-19
US20230181594A1 (en) 2023-06-15
WO2007117971A3 (en) 2007-12-27
ES2752823T3 (es) 2020-04-06
WO2007117971A2 (en) 2007-10-18
SG170044A1 (en) 2011-04-29
PE20080053A1 (es) 2008-03-10
NO341147B1 (no) 2017-09-04
JP2009533333A (ja) 2009-09-17
CL2007000916A1 (es) 2008-01-25
US8664215B2 (en) 2014-03-04
BRPI0710085B1 (pt) 2019-12-17
EA016221B1 (ru) 2012-03-30
EP2004196B1 (en) 2016-06-29
JP2015131820A (ja) 2015-07-23
US20240058355A1 (en) 2024-02-22
DK2004196T3 (en) 2016-09-05
IL194473A0 (en) 2009-08-03
EP2004196A2 (en) 2008-12-24
DK3150209T3 (da) 2019-10-28
EP3150209A1 (en) 2017-04-05
TW200815016A (en) 2008-04-01
NI200800261A (es) 2012-10-30
US10617695B2 (en) 2020-04-14
EA200870396A1 (ru) 2009-04-28
ZA200809327B (en) 2009-12-30
AU2007234957A1 (en) 2007-10-18
ECSP088786A (es) 2009-01-30
MX2008012657A (es) 2009-02-19
US20120094978A1 (en) 2012-04-19
HK1131331A1 (en) 2010-01-22
CA2648115C (en) 2015-03-24
US20170065605A1 (en) 2017-03-09
US20250108059A1 (en) 2025-04-03
JP5292277B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
NO20084593L (no) Okulaere allergibehandlinger
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
WO2009026334A3 (en) Treatment with kallikrein inhibitors
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
TR201818983T4 (tr) İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
NO20091395L (no) Nye tiofenderivater
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
NO20081042L (no) PPAR aktive forbindelser
WO2008106228A3 (en) Methods and compositions for normalizing meibomian gland secretions
MA32934B1 (fr) Combinaisons inhibitrices hsp90
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
CL2008001457A1 (es) Compuestos derivados de 6-(piridin-3-il)quinolina, inhibidores de la pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer en un humano que lo necesite.
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
TR200504892A1 (tr) Belirti göstermeyen tüberküloz tedavisi
AR059928A1 (es) Metodos y dispositivos oftalmicos usados en el tratamiento de alergias oculares
AR059330A1 (es) Composiciones acondicionadoras del cabello
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
NO20090724L (no) Benzylaminer, fremgangsmåte for fremstilling av slike, og anvendelse av dem som betennelseshemmende midler
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
DK1994005T3 (da) Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere
WO2005108416A3 (en) Myosin light chain kinase inhibitors and their use
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: JOHNSON & JOHNSON VISION CARE, US